open access

Vol 87, No 12 (2016)
Research paper
Published online: 2016-12-30
Get Citation

Diagnostic value of CA 19-9 in pregnancies complicated by spinal neural tube defects: a preliminary study

Hakan Timur, Aytekin Tokmak, Aykan Yucel, Hasan Ali Inal, Umran Buyukkagnici, Levent Sirvan, Nuri Danisman
DOI: 10.5603/GP.2016.0093
·
Pubmed: 28098931
·
Ginekol Pol 2016;87(12):808-813.

open access

Vol 87, No 12 (2016)
ORIGINAL PAPERS Obstetrics
Published online: 2016-12-30

Abstract

Objectives: Various physiological and pathological conditions can induce significant variations in plasma concentrations of tumor markers, such as CA 19-9, which is present in the serum and amniotic fluid of pregnant women. Herein, we aimed to determine the clinical importance of maternal serum CA 19-9 levels in the diagnosis of neural tube defects (NTDs).

Material and methods: A total of 100 women were included in this controlled cross-sectional study. Thirty-three patients whose pregnancies were complicated by isolated meningocele or meningomyelocele constituted the study group, whereas 33 normal, healthy pregnant women constituted the control group, and 34 age- and body mass index (BMI)-matched non-pregnant women were chosen for the validation group.

Results: The mean maternal serum CA 19-9 levels were 17.2 ± 17.0 IU/mL, 7.1 ± 5.9 IU/mL, and 4.7 ± 3.6 IU/mL in the study, control, and validation groups, respectively (p < 0.001). ROC analyses showed that elevated CA 19-9 values may predict NTDs (p < 0.001). The cut-off value for CA 19-9 was found to be 9.6 IU/mL at 70% (51%–84%, 95% CI) sensitivity and 84% (74%–92%, 95% CI) specificity.

Conclusions: CA 19-9 may be a promising noninvasive marker for NTDs. Further studies are needed to reveal the clinical applicability and diagnostic potential of maternal serum CA 19-9 levels in the identification of NTDs.

Abstract

Objectives: Various physiological and pathological conditions can induce significant variations in plasma concentrations of tumor markers, such as CA 19-9, which is present in the serum and amniotic fluid of pregnant women. Herein, we aimed to determine the clinical importance of maternal serum CA 19-9 levels in the diagnosis of neural tube defects (NTDs).

Material and methods: A total of 100 women were included in this controlled cross-sectional study. Thirty-three patients whose pregnancies were complicated by isolated meningocele or meningomyelocele constituted the study group, whereas 33 normal, healthy pregnant women constituted the control group, and 34 age- and body mass index (BMI)-matched non-pregnant women were chosen for the validation group.

Results: The mean maternal serum CA 19-9 levels were 17.2 ± 17.0 IU/mL, 7.1 ± 5.9 IU/mL, and 4.7 ± 3.6 IU/mL in the study, control, and validation groups, respectively (p < 0.001). ROC analyses showed that elevated CA 19-9 values may predict NTDs (p < 0.001). The cut-off value for CA 19-9 was found to be 9.6 IU/mL at 70% (51%–84%, 95% CI) sensitivity and 84% (74%–92%, 95% CI) specificity.

Conclusions: CA 19-9 may be a promising noninvasive marker for NTDs. Further studies are needed to reveal the clinical applicability and diagnostic potential of maternal serum CA 19-9 levels in the identification of NTDs.

Get Citation

Keywords

inflammation, meningomyelocele, prenatal screening, spina bifida, tumor markers

About this article
Title

Diagnostic value of CA 19-9 in pregnancies complicated by spinal neural tube defects: a preliminary study

Journal

Ginekologia Polska

Issue

Vol 87, No 12 (2016)

Article type

Research paper

Pages

808-813

Published online

2016-12-30

DOI

10.5603/GP.2016.0093

Pubmed

28098931

Bibliographic record

Ginekol Pol 2016;87(12):808-813.

Keywords

inflammation
meningomyelocele
prenatal screening
spina bifida
tumor markers

Authors

Hakan Timur
Aytekin Tokmak
Aykan Yucel
Hasan Ali Inal
Umran Buyukkagnici
Levent Sirvan
Nuri Danisman

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl